

Pneumococcal Vaccination Recommendations for Children¹ and Adults by Age and/or Risk Factor

Risk Group	Underlying medical condition or other risk factor	Recommendations for Vaccination with Pneumococcal Conjugate Vaccine (PCV13)			Recommendations for Vaccination with Pneumococcal polysaccharide vaccine (PPSV23)		
		Administer doses needed to complete schedule to children through age 71 months	Consider administering 1 dose to PCV13-naïve children age 6–18 years	Administer 1 dose to PCV13-naïve adults age 19 years and older	Administer 1 dose at age 2 through 64 years	Administer second dose 5 years after first dose if age <65 years	Administer 1 dose at age 65 years
Immuno-competent	Healthy adult, non-smoker						X
	Chronic heart disease ²	X			X		X
	Chronic lung disease ³	X			X		X
	Diabetes mellitus	X			X		X
	Cerebrospinal fluid leak	X	X	X	X		X
	Cochlear implant	X	X	X	X		X
	Alcoholism				X		X
	Chronic liver disease, cirrhosis				X		X
	Cigarette smoking (≥19 yrs)				X		X
Functional or anatomic asplenia	Sickle cell disease/other hemoglobinopathy	X	X	X	X	X	X
	Congenital or acquired asplenia	X	X	X	X	X	X
Immuno-compromised	Congenital or acquired immunodeficiency ⁴	X	X	X	X	X	X
	HIV	X	X	X	X	X	X
	Chronic renal failure	X	X	X	X	X	X
	Nephrotic syndrome	X	X	X	X	X	X
	Leukemia	X	X	X	X	X	X
	Lymphoma	X	X	X	X	X	X
	Hodgkin disease	X	X	X	X	X	X
	Generalized malignancy	X	X	X	X	X	X
	Iatrogenic immunosuppression ⁵	X	X	X	X	X	X
	Solid organ transplant	X	X	X	X	X	X
Multiple myeloma	X	X	X	X	X	X	

Technical content reviewed by the Centers for Disease Control and Prevention

IMMUNIZATION ACTION COALITION

1573 Selby Avenue • St. Paul, MN 55104 • 651 647-9009 • www.immunize.org • www.vaccineinformation.org

www.immunize.org/catg.d/p2019.pdf • Item #P2019 (2/13)

1. For PCV13 vaccination of healthy children, see “Recommendations for Pneumococcal Vaccine Use in Children” at www.immunize.org/catg.d/p2016.pdf.

2. Particularly cyanotic congenital heart disease and cardiac failure in children; excluding hypertension in adults.

3. Including asthma in children if treated with high-dose oral corticosteroid therapy; including asthma in adults.

4. Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).

5. Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.